SOM230 Ectopic ACTH-producing Tumors

Summary

The purpose of this prospective open-label phase II study, is to evaluate the efficacy of pasireotide twice daily subcutaneous injections for normalizing 24 hour urine free cortisol in patients with ectopic ACTH-producing tumors as measured by the proportion of patients achieving normal UFC at the end of the study period.

Timeline

Start

2015-12

Primary completion

2018-12

Completion

2019-06

Outcome

Outcome not reported

Stopped: “Due to stringent inclusion/exclusion criteria, study investigator deemed it not feasible.”

Drugs

Indications